Sorin Group announced at the Venice Arrhythmias 2011 Congress, CE mark approval and the European commercial launch of its SonR cardiac resincronisation therapy optimisation system.
The SonR system includes the SonR haemodynamic sensor embedded in the SonRtip atrial pacing lead and the Paradym RF SonR CRT-D device. SonR is the first and only system to provide weekly automatic optimisation during patient’s real life activities as an alternative to in-clinic manual echocardiography-based device optimisation for improved CRT response.
According to the company, promising early clinical results suggest that SonR increases responder rates and reduces heart failure hospitalisations compared with standard medical practice over a one year follow-up.
The result of a 10-year clinical science programme, the SonR sensor uniquely measures patient’s cardiac muscle vibrations. These real-time measurements are transmitted to the CRT-D device which uses them to determine the best settings for the patient. Every week, the system automatically optimises to adapt to the patient’s changing condition. SonR measurements correspond to LVdP/dtmax, the gold standard for assessing left ventricular (LV) contractility, a key indicator of cardiac performance.
“The concordance of the SonR signal with measurements of LVdP/dtmax suggests that this new, operator-independent system is a reliable means of tailored optimisation of CRT devices,” commented Philippe Ritter, University Hospital, Bordeaux, France. “Providing weekly optimisation both at rest and exercise is a significant step forward in the treatment of heart failure patients.”